← United States · Coverage record
US · SEC FORM 4
KALA BIO, Inc.
KALA · Nasdaq · CIK 0001479419 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-12-30 · BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 1,358,824
- Previous report
- 445,421
- Avg daily volume
- 6,221,878
- Days to cover
- ≤ 1.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-12-30 | BAKER BROS. ADVISORS LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC | Purchase (P) | Common Stock | 310,559 | USD 6.44 | USD 2,000,000 | SEC filing ↗ |
| 2020-10-22 | Bazemore Todd | Purchase (P) | Common Stock | 40 | USD 7.60 | USD 304 | SEC filing ↗ |
| 2020-06-05 | Bazemore Todd | Purchase (P) | Common Stock | 2 | USD 13.39 | USD 27 | SEC filing ↗ |
| 2020-03-16 | Bazemore Todd | Purchase (P) | Common Stock | 10,000 | USD 5.75 | USD 57,500 | SEC filing ↗ |
| 2020-03-13 | Grunberg Gregory | Purchase (P) | Common Stock | 2,534,854 | USD 7.89 | USD 19,999,998 | SEC filing ↗ |
| 2020-03-13 | Shah Rajeev M. | Purchase (P) | Common Stock | 6,337,135 | USD 7.89 | USD 49,999,995 | SEC filing ↗ |
| 2020-03-13 | Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP | Purchase (P) | Common Stock | 6,337,135 | USD 7.89 | USD 49,999,995 | SEC filing ↗ |
Form 4 evidence
6 transaction lines in the latest 365-day window; 202 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | Reumuth Mary | Sale (S) | Common Stock | 967 | USD 0.82 | USD 793 | SEC filing ↗ |
| 2025-10-23 | Iwicki Mark T | Sale (S) | Common Stock | 154,894 | USD 0.81 | USD 125,464 | SEC filing ↗ |
| 2025-10-22 | Reumuth Mary | Sale (S) | Common Stock | 32,230 | USD 0.83 | USD 26,751 | SEC filing ↗ |
Show recent Form 4 evidence (6 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | Reumuth Mary | Sale (S) | Common Stock | 967 | USD 0.82 | USD 793 | SEC filing ↗ |
| 2025-10-23 | Iwicki Mark T | Sale (S) | Common Stock | 154,894 | USD 0.81 | USD 125,464 | SEC filing ↗ |
| 2025-10-22 | Reumuth Mary | Sale (S) | Common Stock | 32,230 | USD 0.83 | USD 26,751 | SEC filing ↗ |
| 2025-10-22 | Kharabi Darius | Sale (S) | Common Stock | 20,806 | USD 0.83 | USD 17,269 | SEC filing ↗ |
| 2025-10-22 | Brazzell Romulus K | Sale (S) | Common Stock | 46,748 | USD 0.83 | USD 38,801 | SEC filing ↗ |
| 2025-10-22 | Bazemore Todd | Sale (S) | Common Stock | 47,768 | USD 0.83 | USD 39,647 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | KALA |
| CIK | 0001479419 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 202 transaction lines from 2020-03-11 to 2025-10-23 8 P purchase lines · 80 S sale lines · 114 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.